Anticipating an FDA complete response letter (CRL) for rociletinib, Clovis Oncology Inc. quit enrolling ongoing studies of the drug, withdrew its European marketing authorization application (MAA) filing and expects to trim its headcount by 35 percent from its 2015 level by year-end. In wake of the reckoning, Clovis is turning its full attention to potential approval and commercialization of its PARP 1-3 inhibitor, rucaparib.